PREDICTSELECT is a decision tool developed by researchers at Westmead BCI to identify patients with ER positive and HER2 negative breast cancer who would benefit from EndoPredict testing. The tool uses five variables to provide prediction of high or low risk. Those patients that cannot be classified using these variables may benefit from EndoPredict testing. A statistical model was created to give a predicted EPClin score to aid clinicians in decision making in cases where the risk cannot be confidently predicted. An EPClin score of ≥3.33 corresponds to ≥10% risk of distant recurrence at 10 years if treated with endocrine agent alone for 5 years.